J. Nakata

发表

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

M. Hino, S. Kishida, N. Hosen, 2012, Leukemia.

What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia

Y. Oji, Y. Oka, H. Sugiyama, 2019, Expert review of hematology.

Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects

N. Hosen, Y. Oji, A. Tsuboi, 2014, Expert review of hematology.

Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

N. Hosen, Y. Oji, A. Tsuboi, 2020, Cancer Immunology, Immunotherapy.

An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells

N. Hosen, Y. Oji, A. Tsuboi, 2016, Journal of immunotherapy.

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy

M. Ikawa, N. Hosen, Y. Oji, 2021, bioRxiv.

Frequency of CD4+FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD

H. Tamaki, T. Fujioka, T. Soma, 2013, Bone Marrow Transplantation.

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms

N. Hosen, Y. Oji, A. Tsuboi, 2015, PloS one.

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis

N. Hosen, Y. Oji, A. Tsuboi, 2016, PloS one.

WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives

N. Hosen, Y. Oji, A. Tsuboi, 2016 .

Biased usage of T cell receptor β‐chain variable region genes of Wilms’ tumor gene (WT1)‐specific CD8+ T cells in patients with solid tumors and healthy donors

T. Yoshimine, T. Enomoto, M. Sekimoto, 2012, Cancer Science.

A Zbtb7a proto‐oncogene as a novel target for miR‐125a

N. Hosen, Y. Oji, A. Tsuboi, 2016, Molecular carcinogenesis.

WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies

J. Sakamoto, E. Morii, S. Morita, 2018, International journal of cancer.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides

N. Hosen, Y. Oji, A. Tsuboi, 2018, Oncotarget.

Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning

H. Tamaki, T. Fujioka, T. Soma, 2012, Bone Marrow Transplantation.

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma

J. Sakamoto, S. Morita, N. Hosen, 2018, Cancer Immunology, Immunotherapy.

Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.

N. Hosen, Y. Oji, A. Tsuboi, 2016, Stem cell investigation.

Low incidence of HHV‐6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft‐vs‐host disease prophylaxis compared with cord blood transplantation

H. Tamaki, T. Fujioka, T. Soma, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy

N. Hosen, Y. Oji, A. Tsuboi, 2017, Oncology Research and Treatment.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

T. Yoshimine, J. Sakamoto, S. Morita, 2016, International journal of cancer.

Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

K. Akashi, K. Takenaka, H. Kishima, 2022, Science Translational Medicine.

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

T. Nakao, J. Takagi, K. Takeda, 2017, Nature Medicine.

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1

H. Kishima, M. Ohmi, N. Naka, 2023, Cancers.

Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation

H. Tamaki, T. Fujioka, T. Soma, 2012, Annals of Hematology.

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia

T. Shirakawa, A. Tsuboi, K. Ozono, 2023, BMC Cancer.

A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis

I. Kawase, M. Kawakami, Y. Oka, 2005, European journal of haematology.

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

K. Takeda, T. Shirakawa, A. Tsuboi, 2022, Cancer Immunology, Immunotherapy.

Identification of mouse helper epitopes for WT1-specific CD4+ T cells

N. Hosen, Y. Oji, A. Tsuboi, 2021, Cancer Immunology, Immunotherapy.

Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies

H. Kishima, Y. Oji, A. Tsuboi, 2021, Neuro-oncology advances.

Imaging Assessment of Tumor Response in the Era of Immunotherapy

J. Hatazawa, Y. Oji, A. Tsuboi, 2021, Diagnostics.

Direct antiglobulin test-negative autoimmune hemolytic anemia associated with HLA-haploidentical stem cell transplantation

H. Tamaki, H. Ogawa, J. Nakata, 2011, International journal of hematology.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Y. Takeda, H. Eguchi, Y. Doki, 2014, Journal of immunotherapy.

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

K. Mizuguchi, N. Hosen, Y. Oji, 2016, Future science OA.

Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients

Kenji Mizuguchi, Sumiyuki Nishida, Atsushi Kumanogoh, 2015, Cancer Immunology, Immunotherapy.

Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

N. Hosen, Y. Oji, A. Tsuboi, 2015, Anticancer research.

In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity

N. Hosen, Y. Oji, A. Tsuboi, 2014, Leukemia.

Different mechanisms causing loss of mismatched human leukocyte antigens in relapsing t(6;11)(q27;q23) acute myeloid leukemia after haploidentical transplantation

H. Tamaki, T. Fujioka, H. Ogawa, 2012, European journal of haematology.

Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation

H. Tamaki, T. Fujioka, T. Soma, 2015, Annals of Hematology.

Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse

N. Hosen, Y. Oji, M. Kawakami, 2018, British journal of haematology.

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells

N. Hosen, Y. Oji, A. Tsuboi, 2015, PloS one.

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

M. Hino, N. Hosen, Y. Oji, 2013, Blood Cancer Journal.

Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation.

H. Tamaki, H. Ogawa, J. Nakata, 2011, Leukemia research.

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

E. Morii, N. Naka, N. Hosen, 2022, Oncology letters.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

T. Enomoto, S. Morita, N. Hosen, 2021, Journal of immunotherapy.

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs

Y. Oji, A. Tsuboi, Y. Oka, 2023, Cancer Immunology, Immunotherapy.

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity

Y. Nishida, N. Hosen, Y. Oji, 2018, Oncotarget.

Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects

N. Hosen, Y. Oji, A. Tsuboi, 2014, Expert Review of Hematology.

Biased usage of T cell receptor β‐chain variable region genes of Wilms’ tumor gene (WT1)‐specific CD8+ T cells in patients with solid tumors and healthy donors

T. Yoshimine, T. Enomoto, M. Sekimoto, 2012, Cancer science.

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

T. Nakao, J. Takagi, K. Takeda, 2017, Nature Medicine.

Identification of causative fungus from sterile abscess using metagenomics followed by in situ hybridization

Y. Oka, J. Nakata, H. Nakajima, 2024, Access microbiology.